MAP
EDIT icon

Moody Aldrich Partners’s Editas Medicine EDIT Stock Holding History

Moody Aldrich Partners’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-53,631
Closed -$2.2M – 165
2021
Q3 		$2.2M Buy
+53,631
New +$2.94M 0.28% 91
2018
Q2 		– Sell
-20,836
Closed -$691K – 100
2018
Q1 		$691K Buy
+20,836
New +$742K 0.44% 78

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Moody Aldrich Partners's EDIT Position: Q4 2021 in Review

Moody Aldrich Partners sold out of Editas Medicine (EDIT) in Q4 2021, closing a stake of 53,631 shares — an estimated $2.2M sold.

Moody Aldrich Partners first reported a position in EDIT in Q1 2018 and held it in 2 quarters. The position peaked at $2.2M in Q3 2021. 305 funds tracked by Wall St. Rank hold EDIT as of Q4 2021.

  • Moody Aldrich Partners reported no remaining Editas Medicine position as of Q4 2021 after selling out during the quarter.
  • Moody Aldrich Partners sold 53,631 Editas Medicine shares in Q4 2021, an estimated $2.2M.
  • Moody Aldrich Partners first reported a position in Editas Medicine in Q1 2018 and held it in 2 quarters.
  • Moody Aldrich Partners's Editas Medicine position peaked at $2.2M in Q3 2021.
  • 305 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2021.

Based on Moody Aldrich Partners's 13F filing for Q4 2021, filed 2 Feb 2022.